Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA Study): a multicentre open-label non-randomised clinical trial

INTRODUCTION: Emicizumab prophylaxis substantially reduces bleeding episodes in patients with haemophilia A (HA). The haemostatic efficacy of emicizumab in patients with HA is estimated as approximately 15% based on mimic activity of factor (F) VIII. Although it has been proven effective in preventi...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeyama, Masahiro, Ozu, Naoki, Kasama, Shu, Kasahara, Masato, Matsumoto, Masanori, Shima, Midori, Nogami, Keiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Haematology (Incl Blood Transfusion)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335457/
https://www.ncbi.nlm.nih.gov/pubmed/37429679
http://dx.doi.org/10.1136/bmjopen-2023-072565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335457/
https://www.ncbi.nlm.nih.gov/pubmed/37429679
http://dx.doi.org/10.1136/bmjopen-2023-072565

Ejemplares similares